Patient Access Insights

BeNeLuxA: Options for an early engagement for orphan drugs and ATMPs

In this webinar, we are delighted to be joined by Dr Alexander Natz, Secretary General of EUCOPE, Diane Kleinermans, Advisor to the Ministry of Health and Social Affairs Belgium and Francis Arickx, Advisor at RIZIV-INAMI who will help you understand the opportunities to engage in BeNeLuxA.
Request this webinar

BeNeLuxA: Options for an early engagement for orphan drugs and ATMPs

Originally broadcast: Monday 28th September 2020

Duration: 70 minutes. Available to watch on demand

Learning objectives:

You will understand:

  •  What the options are for companies to engage in BeNeLuxA

  •  What the right point to engage is

  •  How scientific advice and horizon scanning are structured

  •  If BeNeLuxA is a “one-stop-shop” for all participating countries or could the company choose the countries to participate

  •  How confidentiality is secured

  •  What the lessons learnt are from previous BeNeLuxA procedures for orphan drugs, cell & gene therapies and companion diagnostics that sometimes accompany such complex treatments

  •  What the future priorities are from the government/payer perspective.

Who would benefit from registering to attend this webinar:

Anyone with commercial, market access or pricing responsibility for Europe or the BeNeLuxA countries, who may be considering efficiencies from joint HTAs rather than submitting to each individual country.

Speakers

placeholder image

Diane Kleinermans, Advisor to the Ministry of Health and Social Affairs Belgium

Please see their LinkedIn page here.

placeholder image

Francis Arickx, Advisor at RIZIV-INAMI

Please see their LinkedIn page here.

Speaker%20 %20Christian%20Hill

Christian Hill, Chief Executive Officer, MAP BioPharma

Christian is a seasoned Market Access professional with over 20 years of experience in the International Biotech and Pharmaceutical industry. He has been involved in over 50 HTAs across Europe and has built up a strong network of key influencers including EU and national agencies. Prior to co-founding MAP in 2012, he led market access teams and submissions at InterMune, Gilead, Pfizer and Genzyme on a very broad range of products and disease areas from chronic disease to ultra-orphan indications.
Christian is a member of the Board of EUCOPE (European Confederation of Pharmaceutical Entrepreneurs); he is also a member of the Steering Group of EMIG (Ethical Medicines Industry Group) in the UK and Ireland.

Alex Natz

Dr Alexander Natz, Secretary General, EUCOPE

Alexander Natz is the Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (www.eucope.org) in Brussels and works as a lawyer in the healthcare boutique law firm NOVACOS in Düsseldorf (www.novacos-law.com). He advises innovative pharmaceutical and biotech companies, including start-ups, in regulatory and pricing & reimbursement matters from the EU law and German law perspective.

From 2008 to 2013, he was Head of the Brussels Office of Bundesverband der Pharmazeutischen Industrie eV (BPI). Before, he has been a lawyer at Sträter Law Firm in Germany with a special focus on managed entry agreements and licensing of pharmaceuticals. Dr. Natz has also worked in the field of competition law with the European Commission and in the pharmaceutical industry.


Terms and ConditionsComplaints ProcedurePrivacy PolicyCookie Policy

Copyright © 2020. MAP BioPharma Limited. All rights reserved.

MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
United Kingdom

+44 (0) 1480 832360

 enquiries@mapbiopharma.com

MAP BioPharma Limited is a registered company in England and Wales. Company Registration Number 08209281

VAT Group Registration Number GB 292 8576 52